Pomegranate Health advertises compounded semaglutide at $119/month, undercutting most low-cost GLP-1 providers. We compare pricing, dose policies, and service evidence across seven checkout-verified programs to show where Pomegranate saves money and where support and transparency matter most.

Pomegranate Health advertises compounded semaglutide at $119/month and tirzepatide at $149/month with no membership fee. We explain what is included, where the evidence requires checkout confirmation, and how rates compare to PlexusDx all-dose pricing.

Pomegranate Health advertises no membership fee for its GLP-1 weight-loss programs, with compounded semaglutide at $119/month and tirzepatide at $149/month. We document what you pay and what is included.

Pomegranate Health advertises compounded semaglutide at $119/month and tirzepatide at $149/month with monthly billing. No prepaid multi-month plans were documented in September 2026 product-page evidence. We compare those rates to PlexusDx's month-to-month, 3-month, and 6-month prepaid options.

Pomegranate Health advertises $119/month semaglutide and $149/month tirzepatide with "dose tiers in app," but the provider does not publish per-tier pricing on its website. We document what the evidence shows, where it stops, and how PlexusDx's same-price-at-every-dose model compares.

Pomegranate Health advertises $119/month for compounded semaglutide and $149/month for tirzepatide, but dose-tier pricing and checkout variables make long-term cost projections uncertain. We compare the advertised rates to PlexusDx's flat-at-every-dose structure and show the 12-month math.

Pomegranate Health advertises $119/month for compounded semaglutide and $149/month for tirzepatide, while PlexusDx charges $189 and $289 month-to-month. We compare pricing, dose-tier structures, and plan terms using only verified evidence.